Precigen (PGEN) said Tuesday it signed a definitive deal to sell its animal reproductive technologies unit Trans Ova Genetics to URUS for $170 million in...
...
Precigen (PGEN) said Monday the US Food and Drug Administration granted fast track designation to its PRGN-3006 UltraCAR-T treatment for relapsed or...
...
| Address | 20358 Seneca Meadows Parkway Germantown, Maryland 20876 |
| Phone | +1.301.556.9900 |
| Number of Employees | 882 |
| Recent SEC Filing | 07/05/2022 8-K |
| President, Chief Executive Officer & Director | Helen Sabzevari |
| Vice President, Head-Operations & Portfolio | Rutul R. Shah |
| Chief Financial Officer | Harry Thomasian |
| Chief Science Officer | Thomas David Reed |
| Price Open | $1.61 |
| Previous Close | $1.46 |
| 52 Week Range | $1.12 - 6.46 |
| Market Capitalization | $303.2 M |
| Shares Outstanding | 207.7 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/08/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.47 |
| Beta vs. S&P 500 | N/A |
| Revenue | $160.6 M |
| Net Profit Margin | -84.55% |
| Return on Equity | -79.87% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
